- Facultat de Medicina
Centro
![Foto de - Facultat de Medicina](/img/noimage.png)
![Foto de University of Alabama at Birmingham](/img/noimage_org.png)
University of Alabama at Birmingham
Birmingham, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Alabama at Birmingham (11)
2023
-
Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis
JAMA, Vol. 330, Núm. 13, pp. 1266-1277
-
Including measures of chronic kidney disease to improve cardiovascular risk prediction by SCORE2 and SCORE2-OP
European Journal of Preventive Cardiology, Vol. 30, Núm. 1, pp. 8-16
-
Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study
European heart journal, Vol. 44, Núm. 13, pp. 1157-1166
-
Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
Multiple Sclerosis Journal, Vol. 29, Núm. 14, pp. 1776-1785
2022
-
Silver jubilee: 25 years of the first demonstration of the direct effect of phosphate on the parathyroid cell
Nefrologia, Vol. 42, Núm. 6, pp. 645-655
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
2020
-
Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults from 72 datasets
EClinicalMedicine, Vol. 27
-
Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008–2019
Clinical Microbiology and Infection, Vol. 26, Núm. 6, pp. 784.e1-784.e5
2019
-
Adiposity and risk of decline in glomerular filtration rate: Meta-analysis of individual participant data in a global consortium
BMJ (Online), Vol. 364
-
Effect of continuous positive airway pressure in patients with true refractory hypertension and sleep apnea: A post-hoc intention-to-treat analysis of the HIPARCOrandomized clinical trial
Journal of Hypertension, Vol. 37, Núm. 6, pp. 1269-1275
-
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628